Dr. Reddy’s confirms Naloxone Hydrochloride Injection launch in the US
Category: #health  By Saipriya Iyer  Date: 2020-03-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Dr. Reddy’s confirms Naloxone Hydrochloride Injection launch in the US

Dr. Reddy’s Laboratories ,along with its subsidiaries, recently announced that the company has unveiled Naloxone Hydrochloride Injection USP, a prefilled Syringe of single-dose of 2mg/2mL which is a generic version of Narcan Injection USP, approved by the U.S. Food and Drug Administration.

Dr Reddy’s Laboratories’ Chief Executive Officer at North America Generics, Marc Kikuchi stated that the firm is looking forward to rolling out its second product in the market which has already been designated as a CGT (Competitive Generic Therapy) by the U.S. Food and Drug Administration.

Kikuchi further added that the company will have a 180-day of CGT exclusivity on account of the CGT designation to market the product.

According to reliable sources, the Naloxone Hydrochloride Injection USP, 2mg/2mL (1mg/mL) witnessed sales of $31 million MAT across the United States for all the past twelve months up till January 2020.

Apparently, the drug is mainly used to block any effects made by opioids. It is mostly used to reduce the breathing pattern when overdosed on opioid. Naloxone also has the ability to be used in combination with an opioid to lower the risks of misuse of the substances.

Citing sources familiar with the matter, the shares belonging to Dr. Reddy's Laboratories had been slogging down to 3.20% at Rs 2582.45 as the stock has crashed by 10.63% in four different sessions from the closing high of about Rs 2889.90, which had been recorded last on 13 March 2020.

For the record, Dr. Reddy's Laboratories is a pharmaceutical firm based in India. The company provides a vast portfolio of products as well as services with the help of its three different businesses covering global genetics, proprietary products, and pharmaceutical active ingredients and services.

The services provided by the company include custom pharmaceutical services (CPI), differentiated formulations, new chemical entities, generics, active pharmaceutical ingredients (API), and biosimilars.

Source Credit- https://www.business-standard.com/article/news-cm/dr-reddy-s-labs-launches-naloxone-hydrochloride-injection-in-us-120031900747_1.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial
Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial
By Saipriya Iyer

Boehringer Ingelheim, a pharmaceutical company, has recently announced the enrollment of 1st patient in its Phase 3 InPedILD™ trial. The trial will evaluate the dose and safety profile of nintedanib among childre...

Medtronic to turn Hyderabad into R&D hub with $160.3M investment
Medtronic to turn Hyderabad into R&D hub with $160.3M investment
By Saipriya Iyer

Medtronic, a medical device company, has reportedly announced an investment of Rs.1,200 crore ($160.3 million) to turn Hyderabad into its R&D center outside the U.S. The investment has been planned by the company s...

Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
By Saipriya Iyer

Toshiba, a Japanese multinational conglomerate, has reportedly made an exit from the laptop business and transferred its remaining minority stake in the PC business to Sharp. This will mark the company’s terminat...